Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q1 EPS of ($0.35), $0.04 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $6.47 million versus the consensus estimate of $7.82 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.